Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Hum Pathol ; 81: 78-88, 2018 11.
Article in English | MEDLINE | ID: mdl-29958927

ABSTRACT

Composite neoplasms (CNs) are rare and diagnostically challenging lesions that require differentiating between mixed clonal tumors with divergent phenotypes (MT), collision of 2 independent tumors adjacent to each other (CT), and tumor-to-tumor metastasis (TTM). To that end, pathologists have traditionally used immunohistochemistry and limited molecular studies, such as Sanger sequencing. Herein we evaluate the potential application of NGS in the differential diagnosis of these rare neoplasms. Four CNs were included in the study. Two were diagnosed as MT (mixed adenoneuroendocrine carcinoma of the gallbladder and metastatic papillary thyroid carcinoma with squamous dedifferentiation) and 2 were interpreted as TTM (esophageal adenocarcinoma to lung adenocarcinoma and small cell carcinoma of the lung to meningeal melanoma). Diagnoses were made using clinical, histologic, and immunophenotypic information, with the aid of limited molecular studies in 2 cases. Formalin-fixed, paraffin-embedded tissue was dissected for DNA and RNA extraction, and NGS was performed using the Oncomine Comprehensive Panel. The 2 tumors initially interpreted as MT showed shared genetic aberrations in the different neoplastic components, supporting the pathologic diagnosis. NGS results for the lesion diagnosed as esophageal adenocarcinoma metastatic to lung adenocarcinoma did not support the histopathologic interpretation and were deemed inconclusive. However, the identification of an identical CDKN2A mutation in all components and in the adjacent benign lung parenchyma suggests a possible germline aberration. Sequencing results in the last case were clearly supportive of TTM. This study illustrates the role of NGS in the diagnostic workup of CNs, as an adjunct to light microscopy and immunohistochemistry.


Subject(s)
Biomarkers, Tumor/genetics , Gene Expression Profiling/methods , Genetic Variation , High-Throughput Nucleotide Sequencing , Neoplasms, Complex and Mixed/genetics , Aged , Biomarkers, Tumor/analysis , Chicago , Diagnosis, Differential , Female , Genetic Predisposition to Disease , Humans , Immunohistochemistry , Male , Middle Aged , Neoplasms, Complex and Mixed/chemistry , Neoplasms, Complex and Mixed/pathology , Phenotype , Predictive Value of Tests
2.
Transl Res ; 181: 59-70, 2017 03.
Article in English | MEDLINE | ID: mdl-27669488

ABSTRACT

Recent studies have established that a complex community of microbes colonize the human urinary tract; however, their role in kidney transplant patients treated with prophylactic antibiotics remains poorly investigated. Our aim was to investigate the urinary microbiome of kidney transplant recipients. Urine samples from 21 patients after kidney transplantation and 8 healthy controls were collected. All patients received prophylactic treatment with the antibiotic combination trimethoprim-sulfamethoxazole. Metagenomic DNA was isolated from urine samples, sequenced using shotgun sequencing approach on Illumina HiSeq 2000 platform, and analyzed for microbial taxonomic and functional annotations. Our results demonstrate that the urine microbiome of kidney transplants was markedly different at all taxonomic levels from phyla to species, had decreased microbial diversity, and increased abundance of potentially pathogenic species compared with healthy controls. Specifically, at the phylum level, we detected a significant decrease in Actinobacteria and increase in Firmicutes due to increases in Enterococcus faecalis. In addition, there was an increase in the Proteobacteria due to increases in Escherichia coli. Analysis of predicted functions of the urinary metagenome revealed increased abundance of enzymes in the folate pathway including dihydrofolate synthase that are not inhibited by trimethoprim-sulfamethoxazole, but can augment folate metabolism. This report characterizes the urinary microbiome of kidney transplants using shotgun metagenomics approach. Our results indicate that the urinary microbiota may be modified in the context of prophylactic antibiotics, indicating that a therapeutic intervention may shift the urinary microbiota to select bacterial species with increased resistance to antibiotics. The evaluation and development of optimal prophylactic regimens that do not promote antibiotic resistance is an important future goal.


Subject(s)
Drug Resistance, Microbial , Dysbiosis/microbiology , Dysbiosis/urine , Kidney Transplantation , Microbiota , Adult , Aged , Biodiversity , Case-Control Studies , Female , Folic Acid/metabolism , Humans , Kidney Failure, Chronic/diagnosis , Kidney Failure, Chronic/microbiology , Male , Metabolic Networks and Pathways , Middle Aged , Phylogeny , Principal Component Analysis , Urinary Tract Infections/microbiology
3.
Am J Physiol Lung Cell Mol Physiol ; 310(5): L426-38, 2016 Mar 01.
Article in English | MEDLINE | ID: mdl-26684249

ABSTRACT

Triggering receptors expressed on myeloid cell-1 (TREM-1) is a superimmunoglobulin receptor expressed on myeloid cells. Synergy between TREM-1 and Toll-like receptor amplifies the inflammatory response; however, the mechanisms by which TREM-1 accentuates inflammation are not fully understood. In this study, we investigated the role of TREM-1 in a model of LPS-induced lung injury and neutrophilic inflammation. We show that TREM-1 is induced in lungs of mice with LPS-induced acute neutrophilic inflammation. TREM-1 knockout mice showed an improved survival after lethal doses of LPS with an attenuated inflammatory response in the lungs. Deletion of TREM-1 gene resulted in significantly reduced neutrophils and proinflammatory cytokines and chemokines, particularly IL-1ß, TNF-α, and IL-6. Physiologically deletion of TREM-1 conferred an immunometabolic advantage with low oxygen consumption rate (OCR) sparing the respiratory capacity of macrophages challenged with LPS. Furthermore, we show that TREM-1 deletion results in significant attenuation of expression of miR-155 in macrophages and lungs of mice treated with LPS. Experiments with antagomir-155 confirmed that TREM-1-mediated changes were indeed dependent on miR-155 and are mediated by downregulation of suppressor of cytokine signaling-1 (SOCS-1) a key miR-155 target. These data for the first time show that TREM-1 accentuates inflammatory response by inducing the expression of miR-155 in macrophages and suggest a novel mechanism by which TREM-1 signaling contributes to lung injury. Inhibition of TREM-1 using a nanomicellar approach resulted in ablation of neutrophilic inflammation suggesting that TREM-1 inhibition is a potential therapeutic target for neutrophilic lung inflammation and acute respiratory distress syndrome (ARDS).


Subject(s)
Lung Injury/drug therapy , Macrophages/drug effects , Membrane Glycoproteins/metabolism , MicroRNAs/genetics , Receptors, Immunologic/metabolism , Animals , Cytokines/metabolism , Inflammation/metabolism , Lipopolysaccharides/pharmacology , Lung Injury/metabolism , Macrophages/metabolism , Male , Mice, Inbred C57BL , Myeloid Cells/drug effects , Myeloid Cells/metabolism , Nanomedicine/methods , RNA, Small Interfering/metabolism , Triggering Receptor Expressed on Myeloid Cells-1
4.
J Biol Chem ; 289(21): 15118-29, 2014 May 23.
Article in English | MEDLINE | ID: mdl-24711453

ABSTRACT

Triggering receptor expressed on myeloid cells 1 (TREM-1) is a superimmunoglobulin receptor expressed on myeloid cells that plays an important role in the amplification of inflammation. Recent studies suggest a role for TREM-1 in tumor-associated macrophages with relationship to tumor growth and progression. Whether the effects of TREM-1 on inflammation and tumor growth are mediated by an alteration in cell survival signaling is not known. In these studies, we show that TREM-1 knock-out macrophages exhibit an increase in apoptosis of cells in response to lipopolysaccharide (LPS) suggesting a role for TREM-1 in macrophage survival. Specific ligation of TREM-1 with monoclonal TREM-1 (mTREM-1) or overexpression of TREM-1 with adeno-TREM-1 induced B-cell lymphoma-2 (Bcl-2) with depletion of the key executioner caspase-3 prevents the cleavage of poly(ADP-ribose) polymerase. TREM-1 knock-out cells showed lack of induction of Bcl2 with an increase in caspase-3 activation in response to lipopolysaccharide. In addition overexpression of TREM-1 with adeno-TREM-1 led to an increase in mitofusins (MFN1 and MFN2) and knockdown of TREM-1 decreased the expression of mitofusins suggesting that TREM-1 contributes to the maintenance of mitochondrial integrity favoring cell survival. Investigations into potential mechanisms by which TREM-1 alters cell survival showed that TREM-1-induced Bcl-2 in an Egr2-dependent manner. Furthermore, our data shows that expression of Egr2 in response to specific ligation of TREM-1 is ERK mediated. These data for the first time provide novel mechanistic insights into the role of TREM-1 as an anti-apoptotic protein that prolongs macrophage survival.


Subject(s)
Macrophages/metabolism , Membrane Glycoproteins/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , Receptors, Immunologic/metabolism , Animals , Apoptosis/genetics , Apoptosis Regulatory Proteins/genetics , Apoptosis Regulatory Proteins/metabolism , Blotting, Western , Caspase 3/metabolism , Cell Line , Cell Survival/genetics , Cells, Cultured , Early Growth Response Protein 2/genetics , Early Growth Response Protein 2/metabolism , Enzyme Inhibitors/pharmacology , Flow Cytometry , Gene Expression Profiling , Humans , MAP Kinase Kinase 1/antagonists & inhibitors , MAP Kinase Kinase 1/metabolism , Macrophages/cytology , Membrane Glycoproteins/genetics , Mice , Mice, Inbred C57BL , Mitochondria/drug effects , Mitochondria/metabolism , Oligonucleotide Array Sequence Analysis , Poly(ADP-ribose) Polymerases/metabolism , Proto-Oncogene Proteins c-bcl-2/genetics , RNA Interference , Receptors, Immunologic/genetics , Triggering Receptor Expressed on Myeloid Cells-1
5.
J Immunol ; 191(7): 3810-7, 2013 Oct 01.
Article in English | MEDLINE | ID: mdl-24018272

ABSTRACT

Stomatococcus mucilaginosus is an oral commensal that has been occasionally reported to cause severe infections in immunocompromised patients. There is no information about the pathogenic role of S. mucilaginosus in airway infections. In a cohort of 182 subjects with bronchiectasis, we found that 9% were colonized with S. mucilaginosus in their lower airways by culture growth from bronchoalveolar lavage. To address the pathogenic potential of S.mucilaginosus, we developed a murine model of S. mucilaginosus lung infection. Intratracheal injection of S. mucilaginosus in C57BL/6 mice resulted in a neutrophilic influx with production of proinflammatory cytokines, chemokines, and lipid mediators, mainly PGE2 with induction of cyclooxygenase-2 (COX-2) in the lungs. Presence of TLR2 was necessary for induction of COX-2 and production of PGE2 by S. mucilaginosus. TLR2-deficient mice showed an enhanced clearance of S. mucilaginosus compared with wild-type mice. Administration of PGE2 to TLR2(-/-) mice resulted in impaired clearance of S. mucilaginosus, suggesting a key role for COX-2-induced PGE2 production in immune response to S. mucilaginosus. Mechanistically, induction of COX-2 in macrophages was dependent on the p38-ERK/MAPK signaling pathway. Furthermore, mice treated with S. mucilaginosus and Pseudomonas aeruginosa showed an increased mortality compared with mice treated with PA103 or S. mucilaginosus alone. Inhibition of COX-2 significantly improved survival in mice infected with PA103 and S. mucilaginosus. These data provide novel insights into the bacteriology and personalized microbiome in patients with bronchiectasis and suggest a pathogenic role for S. mucilaginosus in patients with bronchiectasis.


Subject(s)
Cyclooxygenase 2/metabolism , Micrococcaceae/pathogenicity , Pneumonia/metabolism , Pneumonia/microbiology , Signal Transduction , Animals , Bronchiectasis/immunology , Bronchiectasis/metabolism , Bronchiectasis/microbiology , Cell Line , Cyclooxygenase Inhibitors/pharmacology , Dinoprostone/biosynthesis , Disease Models, Animal , Female , Humans , Lung/immunology , Lung/metabolism , Lung/microbiology , MAP Kinase Signaling System , Macrophages/immunology , Macrophages/metabolism , Macrophages/microbiology , Male , Mice , Mice, Knockout , Micrococcaceae/immunology , Neutrophil Infiltration/immunology , Pneumonia/immunology , Pneumonia/mortality , Pseudomonas aeruginosa/immunology , Pseudomonas aeruginosa/pathogenicity , Risk Factors , Toll-Like Receptor 2/genetics , Toll-Like Receptor 2/metabolism
6.
Int J Biochem Cell Biol ; 44(11): 2032-43, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22890222

ABSTRACT

Triggering receptor expressed on myeloid cells 1 (TREM-1) is a member of the immunoglobulin superfamily expressed on macrophage and neutrophils and is emerging as a potent amplifier of TLR initiated inflammatory responses. Blockade of TREM-1 improves survival in animal models of sepsis. In this study, we show that curcumin or diferuloylmethane, a yellow pigment present in turmeric, a major ingredient of curry spice inhibited the expression of TREM-1 in vitro in primary bone marrow derived macrophages and in vivo in lungs of mice with sepsis. Chromatin immunoprecipitation assay confirmed that curcumin inhibits the binding of p65 to TREM-1 promoter in response to LPS. Further we show that curcumin inhibited p300 activity in the TREM-1 promoter region leading to hypoacetylation of histone 3 and 4 in the lysine residues. Inhibition of TREM-1 by curcumin is oxidant independent. These studies are the first report to define a detailed molecular mechanism by which curcumin exerts anti-inflammatory effects through regulation of TREM-1 gene activity and provide additional mechanistic insights into the anti-inflammatory effect of curcumin.


Subject(s)
Curcumin/pharmacology , Epigenesis, Genetic/drug effects , Lipopolysaccharides/pharmacology , Membrane Glycoproteins/genetics , Receptors, Immunologic/genetics , Acetylation/drug effects , Animals , Histones/metabolism , Lung/drug effects , Lung/metabolism , Lung/pathology , Macrophages/drug effects , Macrophages/metabolism , Male , Membrane Glycoproteins/metabolism , Methylation/drug effects , Mice , Mice, Inbred C57BL , Promoter Regions, Genetic/genetics , Protein Binding/drug effects , Proto-Oncogene Proteins/metabolism , Reactive Oxygen Species/metabolism , Receptors, Immunologic/metabolism , Sepsis/genetics , Sepsis/pathology , Survival Analysis , Trans-Activators/metabolism , Transcription Factor RelA/metabolism , Triggering Receptor Expressed on Myeloid Cells-1 , p300-CBP Transcription Factors/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...